Novartis Culls Pipeline As ‘Pure-Play’ Drive Progresses
Removes PD-1 Inhibitor, Adds To Radioligand Pipeline
Executive Summary
The Swiss company has raised its 2023 forecast thanks to stronger Q1 sales, but its transformation towards a more ‘pure-play’ pharma company is still a work in progress.
You may also be interested in...
Novartis Has A New Goal: $2bn Peak Sales Per Product
The company said during its R&D day that it has culled its pipeline to 103 clinical stage assets, choosing to focus on drugs that could be big blockbusters.
Novartis Drops BeiGene PD-1 Asset Tevimbra As Drug Wins Esophageal Cancer Nod In Europe
The Swiss drug maker’s decision to give back rights to tislelizumab means BeiGene goes without the potentially $1.55bn in milestone payments the companies had agreed to in early 2021.
Bayer Expands Kerendia Program In Competitive Heart Failure Space
The drug maker added three investigator-initiated studies that will enroll more than 9,000 patients to the existing 6,000-patient MOONRAKER program. It has forecast peak sales of